

REMARKS

Claims 18, 19, 21, and 23-27 are active in the application.

Applicants submit that the application is now ready for examination on the merits.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon  
Attorney of Record  
Registration No. 24,618

Vincent K. Shier, Ph.D.  
Registration No. 50,552



**22850**

Tel.: 703-413-3000  
Fax: 703-413-3220  
NFO:VKS  
E:\202617US0PCT-prl amend.wpd

MARKED-UP COPY

IN THE CLAIMS

Cancel Claims 1-17, 20, and 22.

--18. (Amended) A method of treating a patient having or at risk of a thrombotic disease or [athelosclerosis] atherosclerosis, comprising: administering to said patient an effective dose of a humanized immunoglobulin [which competes with mouse antibody AJvW-2 for specific binding to von Willebrand factor], wherein said humanized immunoglobulin comprises

(a) complementarity determining regions having amino acid sequences RFWMS (31-35), EVNPNDNNTMNYTPSLKD (50-66) and PPYYGSYGGFAY (99-110), in the heavy chain, and RASENIYNNLA (24-34), AATNLAD (50-56) and OHLWTSPYT (89-97), in the light chain, and

(b) framework regions of human antibody.--

--19. (Amended) The method of claim 18, wherein [the immunoglobulin is a humanized form of mouse antibody AJvW-2] the framework regions of a human antibody are from human I3R antibody heavy and light chain frameworks.--

--21. (Amended) The method [according to claims 18-20] of claim 18, wherein the treatment is for stroke, transient ischemic attack, unstable angina, acute myocardial infarction, [angina pectoris,] peripheral vascular disease, deep vein thrombosis, hemolytic uremic syndrome, hemolytic anemia, acute renal failure, thrombotic thrombocytopenic purpura, ischemic complications caused by acute and subacute thrombosis [or], restenosis

after endovascular intervention or preventing ischemic complications caused by reocclusion  
after thrombolytic treatment in acute myocardial infarction as an adjunctive therapy.--

--23-27. (New)--